JP2000517304A - 高分子量のポリマーを基剤とするプロドラッグ - Google Patents
高分子量のポリマーを基剤とするプロドラッグInfo
- Publication number
- JP2000517304A JP2000517304A JP10510949A JP51094998A JP2000517304A JP 2000517304 A JP2000517304 A JP 2000517304A JP 10510949 A JP10510949 A JP 10510949A JP 51094998 A JP51094998 A JP 51094998A JP 2000517304 A JP2000517304 A JP 2000517304A
- Authority
- JP
- Japan
- Prior art keywords
- group
- alkyl
- composition
- substituted
- mmol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/329—Polymers modified by chemical after-treatment with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Polymers & Plastics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Epoxy Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
- Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Polyethers (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.下記の一般式からなる組成物: 式中、 Dは、生物活性成分の残基であり、 Xは、電子求引性基であり、 YおよびY'は、独立にOまたはSであり、 (n)は、ゼロ(0)または正の整数であり、 R1およびR2は、H、C1-6アルキル、アリール、置換アリール、アルアルキル、 ヘテロアルキル、置換ヘテロアルキル、および置換C1-6アルキルからなる群から 独立に選択され、 R3は、実質的に非抗原性のポリマー、C1-12直鎖もしくは分岐アルキルまたは 置換アルキル、C5-8シクロアルキルまたは置換シクロアルキル、カルボキシアル キル、カルボアルコキシアルキル、ジアルキルアミノアルキル、フェニルアルキ R4およびR5は、H、C1-6アルキル、アリール、置換アリール、アルアルキル、 ヘテロアルキル、置換ヘテロアルキル、および置換C1-6アルキルからなる群から 独立に選択されるか、または一緒になって環式C5-7環を形成する、 ただし、nが1で、R3が実質的に非抗原性のポリマーであるとき、R1およびR2 は両方がHであることはない。 2.R3がキャップ形成基Zを有する実質的に非抗原性のポリマーである、請求項 1記載の組成物。 3.ZがOH、C1-4アルキル基または、からなる群から選択され、ここで、D'はD、D以外の生物活性成分、ジアルキル尿 素、C1-4アルキルおよびカルボン酸からなる群から選択される、請求項2記載の 組成物。 4.R1およびR2が独立にH、メチルまたはエチルである、請求項1記載の組成物 。 5.前記の置換C1-6アルキルがカルボキシアルキル、アミノアルキル、ジアルキ ルアミノ、ヒドロキシアルキル、およびメルカプトアルキルからなる群から選択 される、請求項1記載の組成物。 6.XがO,N(R1)、S、SOおよびSO2からなる群から選択される、請求項1記載の 組成物。 7.XがOおよびN(R1)からなる群から選択される、請求項1記載の組成物。 8.(n)がゼロ(0)、1または2である、請求項1記載の組成物。 9.YおよびY'がOである、請求項1記載の組成物。 10.R3がポリアルキレンオキシドを含む、請求項1記載の組成物。 11.前記ポリアルキレンオキシドがポリエチレングリコールを含む、請求項10記 載の組成物。 12.前記ポリアルキレンオキシドが約20,000〜約80,000の分子量を有する、請求 項10記載の組成物。 13.前記ポリアルキレンオキシドが約25,000〜約45,000の分子量を有する、請求 項10記載の組成物。 14.前記ポリアルキレンオキシドが約30,000〜約42,000の分子量を有する、請求 項13記載の組成物。 15.R3が -C(Y)-(CH2)n-(CH2CH2O)x-R"、-C(Y)-Y-(CH2)n-(CH2CH2O)x-R"、-C(Y)-NR1-(CH2 )n-(CH2CH2O)x-R"および-CHR1-(CH2)n-(CH2CH2O)x-R"からな る群から選択され、ここで、 R1は、H、C1-6アルキル、アリール、置換アリール、アルアルキル、ヘテロア ルキル、置換ヘテロアルキル、および置換C1-6アルキルからなる群から独立に選 択され、 (n)は、ゼロ(0)または正の整数であり、 Yは、OまたはSであり、 R"は、キャップ形成基またはR1であり、そして (x)は、重合度を表す、 請求項11記載の組成物。 16.下記の式を有する請求項1記載の組成物: 式中、R1はHまたはCH3であり、そして XはOまたはSである。 17.Dがパクリタキセル、タキソテル、カンプトテシンおよびポドフィロトキシ ンからなる群から選択される、請求項1記載の組成物。 18.Dがパクリタキセルおよびタキソテルからなる群のメンバーであり、Y'が前 記パクリタキセル、タキサンまたはタキソテル残基の2'位置に結合されている 、請求項1記載の組成物。 19.Dがカンプトテシン誘導体残基であり、Y'が前記カンプトテシン誘導体の20S 位置に結合されている、請求項17記載の組成物。 20.Dが生物活性タンパク質、酵素、ペプチド、抗腫瘍薬、心血管薬、抗新生物 薬、抗感染薬、抗カビ剤、抗不安薬、胃腸薬、中枢神経系-活性化薬、鎮痛薬、 排卵誘発剤、避妊薬、抗炎症薬、ステロイド剤、抗尿毒症薬、血管拡張薬および 血管収縮薬からなる群から選択される残基である、請求項1記載の組成物。 21.有効量の請求項1記載の組成物を治療を必要とする哺乳動物に投与すること を含んでなる、プロドラッグによる哺乳動物の治療方法。 22.そのin vivo加水分解半減期よりも長い循環半減期を有するポリマーを基剤 とするプロドラッグの製造方法であって、 有効ヒドロキシル基を含む生物活性成分と、有効カルボン酸基を含む二官能性 スペーサー成分とを、第1のカップリング剤の存在下で反応させて生物活性成分 -スペーサープロドラッグ中間体を形成し、 前記生物活性成分-スペーサープロドラッグ中間体と、カルボン酸、アミンお よびヒドロキシル基からなる群から選択される末端基を含む実質的に非抗原性の ポリマーとを、第2のカップリング剤の存在下で反応させ、そしてポリマーを基 剤とするプロドラッグを回収する、 ことを含んでなる方法。 23.前記生物活性成分が生物活性タンパク質、酵素、ペプチド、抗腫瘍薬、心血 管薬、抗新生物薬、抗感染薬、抗カビ剤、抗不安薬、胃腸薬、中枢神経系-活性 化薬、鎮痛薬、排卵誘発剤、避妊薬、抗炎症薬、ステロイド剤、抗尿毒症薬、血 管拡張薬および血管収縮薬からなる群から選択される、請求項22記載の方法。 24.前記二官能性スペーサー成分がジグリコール酸、チオジグリコール酸、1-ア ラニン、d-アラニン、ヒドロキシ酢酸およびブロモ酢酸からなる群から選択され る、請求項22記載の方法。 25.前記第1および第2のカップリング剤が1,3-ジイソプロピルカルボジイミド (DIPC)、ジアルキルカルボジイミド、ハロゲン化2-ハロ-1-アルキル-ピリジニウ ム、1-(3-ジメチルアミノプロピル)-3-エチルカルボジイミド(EDC)、プロパンホ スホン酸環状無水物(PPACA)およびカルボジイミド(CDI)からなる群から独立に選 択される、請求項22記載の方法。 26.末端カルボン酸基または末端アミン基を含む前記実質的に非抗原性のポリマ ーがポリアルキレンオキシドを含む、請求項22記載の方法。 27.前記ポリアルキレンオキシドが約20,000〜約80,000の分子量を有する、請 求項26記載の方法。 28.生物活性求核試薬コンジュゲートの製造方法であって、 生物活性求核試薬を、式: 〔式中、 Xは、電子求引性基であり、 YおよびY'は、独立にOまたはSであり、 (n)は、ゼロ(0)または正の整数であり、 R1およびR2は、H、C1-6アルキル、アリール、置換アリール、アルアルキル、 ヘテロアルキル、置換ヘテロアルキル、および置換C1-6アルキルからなる群から 独立に選択され、 R3は、実質的に非抗原性のポリマー、C1-12直鎖もしくは分岐アルキルまたは 置換アルキル、C5-8シクロアルキルまたは置換シクロアルキル、カルボキシアル キル、カルボアルコキシアルキル、ジアルキルアミノアルキル、フェニルアルキ ここで、R4およびR5は、H、C1-6アルキル、アリール、置換アリール、アルア ルキル、ヘテロアルキル、置換ヘテロアルキル、および置換C1-6アルキルからな る群から独立に選択されるか、または一緒になって環式C5-7環を形成し、 Z1およびZ2は、独立にCO2H、CO2R6、OR7、CONR1R8、H、C1-4アルキルまたは であり、 ここで、R4およびR5は、H、C1-6アルキル、アリール、置換アリール、アルア ルキル、ヘテロアルキル、置換ヘテロアルキル、および置換C1-6アルキルからな る群から独立に選択されるか、または一緒になって環式C5-7環を形成し、 R6は、R4またはN-ヒドロキシスクシンイミド、N-ヒドロキシベンゾトリアゾー ル、N-アシルタゾリジン、イミダゾールまたは酸活性化基であり、 R7は、R4またはC(O)-ハロゲン、パラニトロフェニルカーボネート、イミダゾ リルカーボネートまたはN-ヒドロキシスクシンイミジルカーボネートであり、そ して R8は、R4またはCR1R2CO2Hである〕 の化合物と接触させ、 得られる生物活性求核試薬コンジュゲートを回収する、 ことを含んでなる方法。 29.カンプトテシンを基剤とするコンジュゲートの製造方法であって、 1) カンプトテシン誘導体と、二官能性スペーサー含有成分とを、カップリン グ剤の存在下で接触させることにより、二官能性スペーサー含有成分を含むカン プトテシン誘導体を形成し、 2) 前記二官能性スペーサー含有成分を含むカンプトテシン誘導体のトリハロ 酢酸誘導体を形成し、そして 3) 前記二官能性スペーサー含有成分を含むカンプトテシン誘導体のトリハロ 酢酸誘導体を、実質的に非抗原性のポリマーの二酸誘導体と反応させる、 ことを含んでなる方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/700,269 US5840900A (en) | 1993-10-20 | 1996-08-20 | High molecular weight polymer-based prodrugs |
US08/700,269 | 1996-08-20 | ||
PCT/US1997/014692 WO1998007713A1 (en) | 1996-08-20 | 1997-08-20 | High molecular weight polymer-based prodrugs |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009270416A Division JP2010100628A (ja) | 1996-08-20 | 2009-11-27 | 高分子量のポリマーを基剤とするプロドラッグ |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2000517304A true JP2000517304A (ja) | 2000-12-26 |
JP2000517304A5 JP2000517304A5 (ja) | 2004-10-28 |
JP5008783B2 JP5008783B2 (ja) | 2012-08-22 |
Family
ID=24812855
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP51094998A Expired - Fee Related JP5008783B2 (ja) | 1996-08-20 | 1997-08-20 | 高分子量のポリマーを基剤とするプロドラッグ |
JP2009270416A Withdrawn JP2010100628A (ja) | 1996-08-20 | 2009-11-27 | 高分子量のポリマーを基剤とするプロドラッグ |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009270416A Withdrawn JP2010100628A (ja) | 1996-08-20 | 2009-11-27 | 高分子量のポリマーを基剤とするプロドラッグ |
Country Status (13)
Country | Link |
---|---|
US (1) | US5840900A (ja) |
EP (1) | EP0923566B1 (ja) |
JP (2) | JP5008783B2 (ja) |
AT (1) | ATE253060T1 (ja) |
AU (1) | AU730244B2 (ja) |
CA (1) | CA2263409C (ja) |
DE (1) | DE69725862T2 (ja) |
DK (1) | DK0923566T3 (ja) |
ES (1) | ES2210564T3 (ja) |
NZ (1) | NZ334283A (ja) |
PT (1) | PT923566E (ja) |
SI (1) | SI0923566T1 (ja) |
WO (1) | WO1998007713A1 (ja) |
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002512265A (ja) * | 1998-04-17 | 2002-04-23 | エンゾン,インコーポレーテッド | 末端分枝ポリマーリンカーおよびそれを含有するポリマーコンジュゲート |
WO2004039869A1 (ja) | 2002-10-31 | 2004-05-13 | Nippon Kayaku Kabushiki Kaisha | カンプトテシン類の高分子誘導体 |
JP2005512991A (ja) * | 2001-11-09 | 2005-05-12 | エンゾン,インコーポレーテッド | 高分子チオール結合プロドラッグ |
JP2005528380A (ja) * | 2002-04-04 | 2005-09-22 | エンゾン,インコーポレーテッド | インドールのポリマー性アシル誘導体 |
JP2007500278A (ja) * | 2003-05-23 | 2007-01-11 | ネクター セラピューティクス アラバマ,コーポレイション | 特定の原子配置を有するポリマー誘導体 |
WO2008041610A1 (fr) * | 2006-10-03 | 2008-04-10 | Nippon Kayaku Kabushiki Kaisha | Mélange d'un dérivé de résorcinol avec un polymère |
US7662781B2 (en) | 2005-01-31 | 2010-02-16 | Eci, Inc. | Immunopotentiating agent |
US8022047B2 (en) | 2005-08-22 | 2011-09-20 | Chugai Seiyaku Kabushiki Kaisha | Combination anticancer agents |
JP4823894B2 (ja) * | 2004-04-09 | 2011-11-24 | 中外製薬株式会社 | 新規水溶性プロドラッグ |
US8188222B2 (en) | 2006-11-08 | 2012-05-29 | Nippon Kayaku Kabushiki Kaisha | High molecular weight derivative of nucleic acid antimetabolite |
US8323669B2 (en) | 2006-03-28 | 2012-12-04 | Nippon Kayaku Kabushiki Kaisha | Polymer conjugate of taxane |
US8334364B2 (en) | 2006-11-06 | 2012-12-18 | Nipon Kayaku Kabushiki Kaisha | High-molecular weight derivative of nucleic acid antimetabolite |
US8703878B2 (en) | 2007-09-28 | 2014-04-22 | Nippon Kayaku Kabushiki Kaisha | High-molecular weight conjugate of steroids |
US8808749B2 (en) | 2009-05-15 | 2014-08-19 | Nippon Kayaku Kabushiki Kaisha | Polymer conjugate of bioactive substance having hydroxy group |
US8920788B2 (en) | 2008-03-18 | 2014-12-30 | Nippon Kayaku Kabushiki Kaisha | High-molecular weight conjugate of physiologically active substances |
US8940332B2 (en) | 2006-05-18 | 2015-01-27 | Nippon Kayaku Kabushiki Kaisha | High-molecular weight conjugate of podophyllotoxins |
US9018323B2 (en) | 2010-11-17 | 2015-04-28 | Nippon Kayaku Kabushiki Kaisha | Polymer derivative of cytidine metabolic antagonist |
US9149540B2 (en) | 2008-05-08 | 2015-10-06 | Nippon Kayaku Kabushiki Kaisha | Polymer conjugate of folic acid or folic acid derivative |
US9346923B2 (en) | 2011-09-11 | 2016-05-24 | Nippon Kayaku Kabushiki Kaisha | Method for manufacturing block copolymer |
US9434822B2 (en) | 2004-09-22 | 2016-09-06 | Nippon Kayaku Kabushiki Kaisha | Block copolymer, micelle preparation, and anticancer agent containing the same as active ingredient |
Families Citing this family (154)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100361933B1 (ko) | 1993-09-08 | 2003-02-14 | 라 졸라 파마슈티칼 컴파니 | 화학적으로정의된비중합성결합가플랫폼분자및그것의콘주게이트 |
US5965566A (en) * | 1993-10-20 | 1999-10-12 | Enzon, Inc. | High molecular weight polymer-based prodrugs |
US6096336A (en) * | 1996-01-30 | 2000-08-01 | The Stehlin Foundation For Cancer Research | Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs |
KR100561788B1 (ko) * | 1996-03-12 | 2006-09-20 | 피지-티엑스엘 컴파니,엘.피. | 수용성파클리탁셀전구약물을포함하는조성물및이러한조성물을포함하는이식가능한의료장치 |
US6214966B1 (en) * | 1996-09-26 | 2001-04-10 | Shearwater Corporation | Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution |
US20050158273A1 (en) * | 1997-09-25 | 2005-07-21 | Harris J. M. | Soluble, degradable polyethylene glycol) derivatives for controllable release of bound molecules into solution |
US6011042A (en) * | 1997-10-10 | 2000-01-04 | Enzon, Inc. | Acyl polymeric derivatives of aromatic hydroxyl-containing compounds |
US6111107A (en) * | 1997-11-20 | 2000-08-29 | Enzon, Inc. | High yield method for stereoselective acylation of tertiary alcohols |
CA2312975C (en) | 1997-12-17 | 2012-08-21 | Enzon, Inc. | Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents |
US6180095B1 (en) * | 1997-12-17 | 2001-01-30 | Enzon, Inc. | Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents |
CA2316834C (en) * | 1998-01-07 | 2006-01-03 | Shearwater Polymers, Inc. | Degradable heterobifunctional poly(ethylene glycol) acrylates and gels and conjugates derived therefrom |
AU760381B2 (en) * | 1998-04-28 | 2003-05-15 | Laboratoires Serono Sa | PEG-LHRH analog conjugates |
US7953788B2 (en) * | 2001-09-29 | 2011-05-31 | Siebel Systems, Inc. | System and method for queuing data for an application server |
CN1762990A (zh) * | 1999-06-08 | 2006-04-26 | 拉卓拉药物公司 | 包含氨基氧基的化合价平台分子 |
WO2001005819A1 (en) * | 1999-07-15 | 2001-01-25 | Kuhnil Pharm. Co., Ltd. | Novel water soluble-cyclosporine conjugated compounds |
US6228855B1 (en) * | 1999-08-03 | 2001-05-08 | The Stehlin Foundation For Cancer Research | Aromatic esters of camptothecins and methods to treat cancers |
US6352996B1 (en) | 1999-08-03 | 2002-03-05 | The Stehlin Foundation For Cancer Research | Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs |
US6380405B1 (en) * | 1999-09-13 | 2002-04-30 | Nobex Corporation | Taxane prodrugs |
US6541508B2 (en) | 1999-09-13 | 2003-04-01 | Nobex Corporation | Taxane prodrugs |
US6713454B1 (en) | 1999-09-13 | 2004-03-30 | Nobex Corporation | Prodrugs of etoposide and etoposide analogs |
US6376470B1 (en) * | 1999-09-23 | 2002-04-23 | Enzon, Inc. | Polymer conjugates of ara-C and ara-C derivatives |
EP2289549A3 (en) | 1999-10-01 | 2011-06-15 | Immunogen, Inc. | Immunoconjugates for treating cancer |
DK1259562T3 (da) * | 1999-12-22 | 2006-04-18 | Nektar Therapeutics Al Corp | Sterisk hindrede derivater af vandoplöselige polymerer |
AU2001257577A1 (en) | 2000-02-28 | 2001-09-03 | Shearwater Corporation | Water-soluble polymer conjugates of artelinic acid |
AU2001268228A1 (en) | 2000-06-08 | 2001-12-17 | La Jolla Pharmaceutical Company | Multivalent platform molecules comprising high molecular weight polyethylene oxide |
AU2001273387A1 (en) * | 2000-07-12 | 2002-01-21 | Gryphon Therapeutics, Inc. | Polymer-modified bioactive synthetic chemokines, and methods for their manufacture and use |
US7118737B2 (en) | 2000-09-08 | 2006-10-10 | Amylin Pharmaceuticals, Inc. | Polymer-modified synthetic proteins |
CN1454097A (zh) * | 2000-09-08 | 2003-11-05 | 格莱风治疗公司 | 聚合物修饰的合成的蛋白质类 |
US6436386B1 (en) | 2000-11-14 | 2002-08-20 | Shearwater Corporation | Hydroxyapatite-targeting poly (ethylene glycol) and related polymers |
US7829074B2 (en) * | 2001-10-18 | 2010-11-09 | Nektar Therapeutics | Hydroxypatite-targeting poly(ethylene glycol) and related polymers |
AU2002251988A1 (en) * | 2001-02-20 | 2002-09-04 | Enzon, Inc. | Terminally-branched polymeric linkers and polymeric conjugates containing the same |
JP2004530736A (ja) * | 2001-02-20 | 2004-10-07 | エンゾン ファーマシューティカルズ,インコーポレーテッド | 末端分枝高分子リンカーおよびそれを含む高分子複合体 |
US20040077835A1 (en) * | 2001-07-12 | 2004-04-22 | Robin Offord | Chemokine receptor modulators, production and use |
GB0202906D0 (en) | 2002-02-07 | 2002-03-27 | Univ London | Prevention of myocardial damage |
DE10209821A1 (de) | 2002-03-06 | 2003-09-25 | Biotechnologie Ges Mittelhesse | Kopplung von Proteinen an ein modifiziertes Polysaccharid |
DE10209822A1 (de) * | 2002-03-06 | 2003-09-25 | Biotechnologie Ges Mittelhesse | Kopplung niedermolekularer Substanzen an ein modifiziertes Polysaccharid |
AU2003221291A1 (en) * | 2002-03-13 | 2003-09-22 | Beijing Jiankai Technology Co., Ltd. | Hydrophilic polymer derivate with y type branch and preparation method of it medical composite comprising above compound |
CN100393724C (zh) * | 2002-07-12 | 2008-06-11 | 中国医学科学院药物研究所 | 20-位酯化的喜树碱衍生物及其制法和其药物组合物与用途 |
US7569214B2 (en) | 2002-09-09 | 2009-08-04 | Nektar Therapeutics Al, Corporation | Method for preparing water-soluble polymer derivatives bearing a terminal carboxylic acid |
JP4764630B2 (ja) | 2002-09-09 | 2011-09-07 | ネクター セラピューティックス | 水溶性ポリマーアルカナール |
KR101045422B1 (ko) * | 2002-09-11 | 2011-06-30 | 프레제니우스 카비 도이치란트 게엠베하 | 하이드록시알킬 전분 유도체의 제조 방법 |
US8129330B2 (en) * | 2002-09-30 | 2012-03-06 | Mountain View Pharmaceuticals, Inc. | Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof |
US20040062748A1 (en) * | 2002-09-30 | 2004-04-01 | Mountain View Pharmaceuticals, Inc. | Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof |
WO2004061094A1 (en) | 2002-12-30 | 2004-07-22 | Gryphon Therapeutics, Inc. | Water-soluble thioester and selenoester compounds and methods for making and using the same |
WO2004082629A2 (en) * | 2003-03-17 | 2004-09-30 | Albany Molecular Research, Inc. | Novel cyclosporins |
US7947261B2 (en) | 2003-05-23 | 2011-05-24 | Nektar Therapeutics | Conjugates formed from polymer derivatives having particular atom arrangements |
US7342114B2 (en) * | 2003-07-01 | 2008-03-11 | California Pacific Medical Center | Podophyllotoxin derivatives |
WO2005014655A2 (en) * | 2003-08-08 | 2005-02-17 | Fresenius Kabi Deutschland Gmbh | Conjugates of hydroxyalkyl starch and a protein |
BRPI0413450A (pt) * | 2003-08-08 | 2006-10-17 | Fresenius Kabi De Gmbh | conjugados de hidroxialquil amido e g-csf |
US8394365B2 (en) | 2003-09-17 | 2013-03-12 | Nektar Therapeutics | Multi-arm polymer prodrugs |
KR101200729B1 (ko) * | 2003-09-17 | 2012-11-13 | 넥타르 테라퓨틱스 | 다분지형 고분자 전구약물 |
US20050153371A1 (en) * | 2004-01-07 | 2005-07-14 | Ambit Biosciences Corporation | Conjugated small molecules |
CA2553528C (en) * | 2004-01-21 | 2012-12-04 | Nektar Therapeutics Al, Corporation | Method of preparing propionic acid-terminated polymers |
ES2390885T3 (es) * | 2004-03-11 | 2012-11-19 | Fresenius Kabi Deutschland Gmbh | Conjugados de hidroxialquilalmidón y una proteína |
WO2005092928A1 (en) | 2004-03-11 | 2005-10-06 | Fresenius Kabi Deutschland Gmbh | Conjugates of hydroxyalkyl starch and a protein, prepared by reductive amination |
US8614228B2 (en) | 2004-08-11 | 2013-12-24 | Arqule, Inc. | Quinone prodrug compositions and methods of use |
EP1877097B1 (en) * | 2004-08-11 | 2012-06-20 | Arqule, Inc. | Aminoacid conjugates of beta-lapachone for tumor targeting |
EP1809656A4 (en) * | 2004-09-29 | 2009-03-25 | Amr Technology Inc | CYCLOSPORINAL KINANALOGA AND ITS PHARMACEUTICAL APPLICATIONS |
EP1804823A4 (en) * | 2004-09-29 | 2010-06-09 | Amr Technology Inc | NEW CYCLOSPORIN ANALOGUE AND ITS PHARMACEUTICAL APPLICATIONS |
WO2006041631A2 (en) * | 2004-10-06 | 2006-04-20 | Amr Technology, Inc. | Novel cyclosporin alkynes and their utility as pharmaceutical agents |
EP1861124A2 (en) * | 2005-03-11 | 2007-12-05 | Fresenius Kabi Deutschland GmbH | Production of bioactive glycoproteins from inactive starting materials by conjugation with hydroxyalkylstarch |
JP2008533114A (ja) * | 2005-03-18 | 2008-08-21 | ユーシーエル ビジネス パブリック リミテッド カンパニー | メカノ成長因子ペプチドおよびその使用 |
CA2602654A1 (en) | 2005-04-05 | 2006-10-12 | Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa | Method for shielding functional sites or epitopes on proteins |
EP1762250A1 (en) * | 2005-09-12 | 2007-03-14 | Fresenius Kabi Deutschland GmbH | Conjugates of hydroxyalkyl starch and an active substance, prepared by chemical ligation via thiazolidine |
EP1968644B1 (en) | 2005-12-16 | 2012-06-27 | Nektar Therapeutics | Polymer conjugates of glp-1 |
US7671067B2 (en) * | 2006-02-09 | 2010-03-02 | Enzon Pharmaceuticals, Inc. | Treatment of non-hodgkin's lymphomas with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamtothecin |
US7462627B2 (en) * | 2006-02-09 | 2008-12-09 | Enzon Pharmaceuticals, Inc. | Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers |
KR101513732B1 (ko) * | 2006-02-21 | 2015-04-21 | 넥타르 테라퓨틱스 | 분할된 분해가능한 폴리머 및 이로부터 제조된 컨주게이트 |
US7696165B2 (en) * | 2006-03-28 | 2010-04-13 | Albany Molecular Research, Inc. | Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders |
US7696166B2 (en) * | 2006-03-28 | 2010-04-13 | Albany Molecular Research, Inc. | Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders |
US20080096819A1 (en) * | 2006-05-02 | 2008-04-24 | Allozyne, Inc. | Amino acid substituted molecules |
JP5313129B2 (ja) | 2006-05-02 | 2013-10-09 | アロザイン, インコーポレイテッド | 非天然アミノ酸置換ポリペプチド |
WO2008034019A2 (en) | 2006-09-13 | 2008-03-20 | Polymerix Corporation | Active agents and their oligomers and polymers |
KR20090057235A (ko) * | 2006-09-15 | 2009-06-04 | 엔존 파마슈티컬즈, 인코포레이티드 | 리신계 폴리머 링커 |
KR20090083334A (ko) * | 2006-09-15 | 2009-08-03 | 엔존 파마슈티컬즈, 인코포레이티드 | 방해된 에스테르 기재 생분해성 링커를 갖는 폴리알킬렌 옥시드 |
US8110559B2 (en) * | 2006-09-15 | 2012-02-07 | Enzon Pharmaceuticals, Inc. | Hindered ester-based biodegradable linkers for oligonucleotide delivery |
US7985783B2 (en) | 2006-09-21 | 2011-07-26 | The Regents Of The University Of California | Aldehyde tags, uses thereof in site-specific protein modification |
WO2008066902A2 (en) | 2006-11-30 | 2008-06-05 | Nektar Therapeutics Al, Corporation | Method for preparing a polymer conjugate |
BRPI0807232A2 (pt) * | 2007-02-09 | 2014-04-29 | Enzon Pharmaceuticals Inc | Tratamento de cânceres resistentes ou refratários com conjugados poliméricos multi-braços de 7-etil-10-hidroxicamptotecina |
ES2532656T3 (es) * | 2007-04-30 | 2015-03-30 | Arqule, Inc. | Compuestos de hidroxi sulfonato de quinona y sus usos |
CA2707840A1 (en) * | 2007-08-20 | 2009-02-26 | Allozyne, Inc. | Amino acid substituted molecules |
WO2009025669A1 (en) * | 2007-08-20 | 2009-02-26 | Enzon Pharmaceuticals, Inc. | Polymeric linkers containing pyridyl disulfide moieties |
WO2009055014A2 (en) * | 2007-10-23 | 2009-04-30 | Nektar Therapeutics Al, Corporation | Hydroxyapatite-targeting multiarm polymers and conjugates made therefrom |
EP2070950A1 (en) * | 2007-12-14 | 2009-06-17 | Fresenius Kabi Deutschland GmbH | Hydroxyalkyl starch derivatives and process for their preparation |
EP2070951A1 (en) * | 2007-12-14 | 2009-06-17 | Fresenius Kabi Deutschland GmbH | Method for producing a hydroxyalkyl starch derivatives with two linkers |
MX2011001583A (es) | 2008-08-11 | 2011-04-04 | Nektar Therapeutics | Conjugados de alcanoato polimericos de multiples brazos. |
TW201010732A (en) * | 2008-08-29 | 2010-03-16 | Enzon Pharmaceuticals Inc | Method of treating RAS associated cancer |
MX2011003117A (es) | 2008-09-19 | 2011-04-21 | Nektar Therapeutics | Conjugados polimericos de peptidos terapeuticos. |
EP2340050A2 (en) * | 2008-09-19 | 2011-07-06 | Nektar Therapeutics | Polymer conjugates of aod-like peptides |
US20110171166A1 (en) * | 2008-09-19 | 2011-07-14 | Nektar Therapeutics | Polymer conjugates of osteocalcin peptides |
US20110171161A1 (en) * | 2008-09-19 | 2011-07-14 | Nektar Therapeutics | Polymer conjugates of protegrin peptides |
US20110171164A1 (en) * | 2008-09-19 | 2011-07-14 | Nektar Therapeutics | Polymer conjugates of glp-2-like peptides |
EP2340047A1 (en) * | 2008-09-19 | 2011-07-06 | Nektar Therapeutics | Polymer conjugates of kiss1 peptides |
WO2010033222A2 (en) * | 2008-09-19 | 2010-03-25 | Netkar Therapeutics | Polymer conjugates of ziconotide peptides |
US20110206633A1 (en) * | 2008-09-19 | 2011-08-25 | Nektar Therapectics | Polymer conjugates of cd-np peptides |
WO2010033227A1 (en) * | 2008-09-19 | 2010-03-25 | Nektar Therapeutics | Polymer conjugates of thymosin alpha 1 peptides |
US20110171165A1 (en) * | 2008-09-19 | 2011-07-14 | Nektar Therapeutics | Polymer conjugates of opioid growth factor peptides |
EP2334333A1 (en) * | 2008-09-19 | 2011-06-22 | Nektar Therapeutics | Polymer conjugates of v681-like peptides |
US20110165112A1 (en) * | 2008-09-19 | 2011-07-07 | Nektar Therapeutics | Polymer conjugates of c-peptides |
CA2736939C (en) | 2008-09-23 | 2021-09-14 | Nektar Therapeutics | Means of achieving sustained-therapeutic sn-38 concentrations in a subject |
AU2009307922A1 (en) * | 2008-10-21 | 2010-04-29 | Enzon Pharmaceuticals, Inc. | Treatment of neuroblastoma with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin |
MX2012013375A (es) | 2010-05-17 | 2013-04-11 | Cebix Inc | Peptido c pegilado. |
EP2590680A1 (en) | 2010-07-09 | 2013-05-15 | Fresenius Kabi Deutschland GmbH | Conjugates comprising hydroxyalkyl starch and a cytotoxic agent and process for their preparation |
WO2012004009A1 (en) | 2010-07-09 | 2012-01-12 | Fresenius Kabi Deutschland Gmbh | Conjugates comprising hydroxyalkyl starch and a cytotoxic agent and process for their preparation |
WO2012004008A1 (en) | 2010-07-09 | 2012-01-12 | Fresenius Kabi Deutschland Gmbh | Conjugates comprising hydroxyalkyl starch and a cytotoxic agent and process for their preparation |
WO2012004006A1 (en) | 2010-07-09 | 2012-01-12 | Fresenius Kabi Deutschland Gmbh | Conjugates comprising hydroxyalkyl starch and a cytotoxic agent and process for their preparation |
CN102339813A (zh) | 2010-07-14 | 2012-02-01 | 中国科学院微电子研究所 | 半导体结构及其制造方法 |
WO2012088445A1 (en) | 2010-12-22 | 2012-06-28 | Nektar Therapeutics | Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds |
WO2012088422A1 (en) | 2010-12-22 | 2012-06-28 | Nektar Therapeutics | Multi-arm polymeric prodrug conjugates of taxane-based compounds |
ES2834992T3 (es) * | 2011-06-06 | 2021-06-21 | Starpharma Pty Ltd | Macromoléculas |
PL2717917T3 (pl) | 2011-07-05 | 2016-12-30 | Koniugaty p97 - przeciwciało | |
CN103083680B (zh) | 2011-11-07 | 2014-12-24 | 北京键凯科技有限公司 | 聚乙二醇-氨基酸寡肽-依诺替康药物结合物及其药物组合物 |
EP2797597B1 (en) | 2011-12-28 | 2020-02-26 | Global Blood Therapeutics, Inc. | Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation |
PE20221914A1 (es) | 2011-12-28 | 2022-12-23 | Global Blood Therapeutics Inc | Compuestos de benzaldehido sustituidos y metodos para su uso en incrementar la oxigenacion del tejido |
JP6433424B2 (ja) | 2012-07-31 | 2018-12-05 | バイオアシス テクノロジーズ インコーポレイテッド | 脱リン酸化されたリソソーム蓄積症タンパク質およびその使用方法 |
EP2916835A4 (en) | 2012-11-12 | 2016-07-27 | Redwood Bioscience Inc | COMPOUNDS AND METHOD FOR PRODUCING A CONJUGATE |
CA2890906A1 (en) | 2012-11-16 | 2014-05-22 | The Regents Of The University Of California | Pictet-spengler ligation for protein chemical modification |
US9310374B2 (en) | 2012-11-16 | 2016-04-12 | Redwood Bioscience, Inc. | Hydrazinyl-indole compounds and methods for producing a conjugate |
BR112015022416A2 (pt) | 2013-03-13 | 2017-10-24 | Bioasis Technologies Inc | fragmentos de p97 e seus usos |
US9604999B2 (en) | 2013-03-15 | 2017-03-28 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US9422279B2 (en) | 2013-03-15 | 2016-08-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US10266551B2 (en) | 2013-03-15 | 2019-04-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US9458139B2 (en) | 2013-03-15 | 2016-10-04 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US10100043B2 (en) | 2013-03-15 | 2018-10-16 | Global Blood Therapeutics, Inc. | Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation |
US20140274961A1 (en) | 2013-03-15 | 2014-09-18 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
KR101971385B1 (ko) | 2013-03-15 | 2019-04-22 | 글로벌 블러드 테라퓨틱스, 인크. | 헤모글로빈 조정을 위한 화합물 및 이의 용도 |
CN112500338A (zh) | 2013-03-15 | 2021-03-16 | 全球血液疗法股份有限公司 | 化合物及其用于调节血红蛋白的用途 |
AU2014237330A1 (en) | 2013-03-15 | 2015-09-17 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US9802900B2 (en) | 2013-03-15 | 2017-10-31 | Global Blood Therapeutics, Inc. | Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin |
US8952171B2 (en) | 2013-03-15 | 2015-02-10 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
WO2015031673A2 (en) | 2013-08-28 | 2015-03-05 | Bioasis Technologies Inc. | Cns-targeted conjugates having modified fc regions and methods of use thereof |
EA201992707A1 (ru) | 2013-11-18 | 2020-06-30 | Глобал Блад Терапьютикс, Инк. | Соединения и их применения для модуляции гемоглобина |
WO2015081282A1 (en) | 2013-11-27 | 2015-06-04 | Redwood Bioscience, Inc. | Hydrazinyl-pyrrolo compounds and methods for producing a conjugate |
AU2015214182B2 (en) | 2014-02-07 | 2020-04-30 | Global Blood Therapeutics, Inc. | Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
MA41841A (fr) | 2015-03-30 | 2018-02-06 | Global Blood Therapeutics Inc | Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs |
EP3371192B1 (en) | 2015-10-27 | 2020-06-03 | California Pacific Medical Center | Podophyllotoxin derivatives and their use |
US10087194B2 (en) | 2015-10-27 | 2018-10-02 | California Pacific Medical Center | Podophyllotoxin derivatives and their use |
MA43373A (fr) | 2015-12-04 | 2018-10-10 | Global Blood Therapeutics Inc | Régimes posologiques pour 2-hydroxy-6-((2- (1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)méthoxy)benzaldéhyde |
TWI663160B (zh) | 2016-05-12 | 2019-06-21 | 全球血液治療公司 | 用於合成2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)-吡啶-3-基)甲氧基)苯甲醛之方法 |
TW202332423A (zh) | 2016-10-12 | 2023-08-16 | 美商全球血液治療公司 | 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑 |
KR102459469B1 (ko) | 2016-11-14 | 2022-10-26 | 항저우 디에이씨 바이오테크 씨오, 엘티디 | 결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용 |
US11492493B2 (en) | 2017-12-26 | 2022-11-08 | Becton, Dickinson And Company | Deep ultraviolet-excitable water-solvated polymeric dyes |
EP3775052B1 (en) | 2018-03-30 | 2024-06-05 | Becton, Dickinson and Company | Water-soluble polymeric dyes having pendant chromophores |
CA3106568A1 (en) | 2018-07-19 | 2020-01-23 | Starpharma Pty Ltd | Therapeutic dendrimer |
CA3107332A1 (en) | 2018-07-22 | 2020-01-30 | Bioasis Technologies Inc. | Treatment of lymphatic metastases |
AU2019325261A1 (en) * | 2018-08-22 | 2021-03-18 | Bacainn Biotherapeutics, Ltd. | Cyclosporine compositions and methods of use |
CN110862400A (zh) * | 2018-08-27 | 2020-03-06 | 遵义医学院 | 喜树碱-羟基乙酸中间体的制备工艺 |
WO2020072377A1 (en) | 2018-10-01 | 2020-04-09 | Global Blood Therapeutics, Inc. | Modulators of hemoglobin for the treatment of sickle cell disease |
US20210355468A1 (en) | 2020-05-18 | 2021-11-18 | Bioasis Technologies, Inc. | Compositions and methods for treating lewy body dementia |
US20210393787A1 (en) | 2020-06-17 | 2021-12-23 | Bioasis Technologies, Inc. | Compositions and methods for treating frontotemporal dementia |
CA3128035A1 (en) | 2020-08-13 | 2022-02-13 | Bioasis Technologies, Inc. | Combination therapies for delivery across the blood brain barrier |
EP4155349A1 (en) | 2021-09-24 | 2023-03-29 | Becton, Dickinson and Company | Water-soluble yellow green absorbing dyes |
WO2024007016A2 (en) | 2022-07-01 | 2024-01-04 | Beckman Coulter, Inc. | Novel fluorescent dyes and polymers from dihydrophenanthrene derivatives |
WO2024044327A1 (en) | 2022-08-26 | 2024-02-29 | Beckman Coulter, Inc. | Dhnt monomers and polymer dyes with modified photophysical properties |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995011020A1 (en) * | 1993-10-20 | 1995-04-27 | Enzon, Inc. | 2'- and/or 7- substituted taxoids |
WO1996023794A1 (en) * | 1995-01-30 | 1996-08-08 | Enzon, Inc. | High molecular weight polymer-based prodrugs |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4644072A (en) * | 1985-04-12 | 1987-02-17 | Bristol-Myers Company | Intermediates for the production of epipodophyllotoxin and related compounds and processes for the preparation and use thereof |
US5157075A (en) * | 1990-05-02 | 1992-10-20 | Taenaka Mining Co., Ltd. | Modified melanin |
US5284865A (en) * | 1991-09-23 | 1994-02-08 | Holton Robert A | Cyclohexyl substituted taxanes and pharmaceutical compositions containing them |
AU4406793A (en) * | 1992-06-04 | 1993-12-30 | Clover Consolidated, Limited | Water-soluble polymeric carriers for drug delivery |
GB9213077D0 (en) * | 1992-06-19 | 1992-08-05 | Erba Carlo Spa | Polymerbound taxol derivatives |
US5614549A (en) * | 1992-08-21 | 1997-03-25 | Enzon, Inc. | High molecular weight polymer-based prodrugs |
WO1994005282A1 (en) * | 1992-09-04 | 1994-03-17 | The Scripps Research Institute | Water soluble taxol derivatives |
US5298643A (en) * | 1992-12-22 | 1994-03-29 | Enzon, Inc. | Aryl imidate activated polyalkylene oxides |
US5321095A (en) * | 1993-02-02 | 1994-06-14 | Enzon, Inc. | Azlactone activated polyalkylene oxides |
WO1994020089A1 (en) * | 1993-03-09 | 1994-09-15 | Enzon, Inc. | Taxol-based compositions with enhanced bioactivity |
US5547981A (en) * | 1993-03-09 | 1996-08-20 | Enzon, Inc. | Taxol-7-carbazates |
US5489589A (en) * | 1994-12-07 | 1996-02-06 | Bristol-Myers Squibb Company | Amino acid derivatives of paclitaxel |
-
1996
- 1996-08-20 US US08/700,269 patent/US5840900A/en not_active Expired - Lifetime
-
1997
- 1997-08-20 AT AT97938484T patent/ATE253060T1/de not_active IP Right Cessation
- 1997-08-20 WO PCT/US1997/014692 patent/WO1998007713A1/en active IP Right Grant
- 1997-08-20 ES ES97938484T patent/ES2210564T3/es not_active Expired - Lifetime
- 1997-08-20 CA CA2263409A patent/CA2263409C/en not_active Expired - Fee Related
- 1997-08-20 AU AU40794/97A patent/AU730244B2/en not_active Ceased
- 1997-08-20 EP EP97938484A patent/EP0923566B1/en not_active Expired - Lifetime
- 1997-08-20 DE DE69725862T patent/DE69725862T2/de not_active Expired - Lifetime
- 1997-08-20 JP JP51094998A patent/JP5008783B2/ja not_active Expired - Fee Related
- 1997-08-20 PT PT97938484T patent/PT923566E/pt unknown
- 1997-08-20 DK DK97938484T patent/DK0923566T3/da active
- 1997-08-20 SI SI9730607T patent/SI0923566T1/xx unknown
- 1997-08-20 NZ NZ334283A patent/NZ334283A/xx active IP Right Revival
-
2009
- 2009-11-27 JP JP2009270416A patent/JP2010100628A/ja not_active Withdrawn
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995011020A1 (en) * | 1993-10-20 | 1995-04-27 | Enzon, Inc. | 2'- and/or 7- substituted taxoids |
WO1996023794A1 (en) * | 1995-01-30 | 1996-08-08 | Enzon, Inc. | High molecular weight polymer-based prodrugs |
Cited By (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4860813B2 (ja) * | 1998-04-17 | 2012-01-25 | エンゾン ファーマシューティカルズ,インコーポレーテッド | 末端分枝ポリマーリンカーおよびそれを含有するポリマーコンジュゲート |
JP2002512265A (ja) * | 1998-04-17 | 2002-04-23 | エンゾン,インコーポレーテッド | 末端分枝ポリマーリンカーおよびそれを含有するポリマーコンジュゲート |
JP2005512991A (ja) * | 2001-11-09 | 2005-05-12 | エンゾン,インコーポレーテッド | 高分子チオール結合プロドラッグ |
JP2005528380A (ja) * | 2002-04-04 | 2005-09-22 | エンゾン,インコーポレーテッド | インドールのポリマー性アシル誘導体 |
WO2004039869A1 (ja) | 2002-10-31 | 2004-05-13 | Nippon Kayaku Kabushiki Kaisha | カンプトテシン類の高分子誘導体 |
JP2007500278A (ja) * | 2003-05-23 | 2007-01-11 | ネクター セラピューティクス アラバマ,コーポレイション | 特定の原子配置を有するポリマー誘導体 |
JP4823894B2 (ja) * | 2004-04-09 | 2011-11-24 | 中外製薬株式会社 | 新規水溶性プロドラッグ |
US9434822B2 (en) | 2004-09-22 | 2016-09-06 | Nippon Kayaku Kabushiki Kaisha | Block copolymer, micelle preparation, and anticancer agent containing the same as active ingredient |
US7662781B2 (en) | 2005-01-31 | 2010-02-16 | Eci, Inc. | Immunopotentiating agent |
US8022047B2 (en) | 2005-08-22 | 2011-09-20 | Chugai Seiyaku Kabushiki Kaisha | Combination anticancer agents |
US8323669B2 (en) | 2006-03-28 | 2012-12-04 | Nippon Kayaku Kabushiki Kaisha | Polymer conjugate of taxane |
US8940332B2 (en) | 2006-05-18 | 2015-01-27 | Nippon Kayaku Kabushiki Kaisha | High-molecular weight conjugate of podophyllotoxins |
WO2008041610A1 (fr) * | 2006-10-03 | 2008-04-10 | Nippon Kayaku Kabushiki Kaisha | Mélange d'un dérivé de résorcinol avec un polymère |
JP5548364B2 (ja) * | 2006-10-03 | 2014-07-16 | 日本化薬株式会社 | レゾルシノール誘導体の高分子結合体 |
US8334364B2 (en) | 2006-11-06 | 2012-12-18 | Nipon Kayaku Kabushiki Kaisha | High-molecular weight derivative of nucleic acid antimetabolite |
US8188222B2 (en) | 2006-11-08 | 2012-05-29 | Nippon Kayaku Kabushiki Kaisha | High molecular weight derivative of nucleic acid antimetabolite |
US8703878B2 (en) | 2007-09-28 | 2014-04-22 | Nippon Kayaku Kabushiki Kaisha | High-molecular weight conjugate of steroids |
USRE46190E1 (en) | 2007-09-28 | 2016-11-01 | Nippon Kayaku Kabushiki Kaisha | High-molecular weight conjugate of steroids |
US8920788B2 (en) | 2008-03-18 | 2014-12-30 | Nippon Kayaku Kabushiki Kaisha | High-molecular weight conjugate of physiologically active substances |
US9149540B2 (en) | 2008-05-08 | 2015-10-06 | Nippon Kayaku Kabushiki Kaisha | Polymer conjugate of folic acid or folic acid derivative |
US8808749B2 (en) | 2009-05-15 | 2014-08-19 | Nippon Kayaku Kabushiki Kaisha | Polymer conjugate of bioactive substance having hydroxy group |
US9018323B2 (en) | 2010-11-17 | 2015-04-28 | Nippon Kayaku Kabushiki Kaisha | Polymer derivative of cytidine metabolic antagonist |
US9346923B2 (en) | 2011-09-11 | 2016-05-24 | Nippon Kayaku Kabushiki Kaisha | Method for manufacturing block copolymer |
Also Published As
Publication number | Publication date |
---|---|
US5840900A (en) | 1998-11-24 |
JP2010100628A (ja) | 2010-05-06 |
CA2263409C (en) | 2011-02-22 |
DK0923566T3 (da) | 2004-03-08 |
CA2263409A1 (en) | 1998-02-26 |
WO1998007713A1 (en) | 1998-02-26 |
ATE253060T1 (de) | 2003-11-15 |
EP0923566B1 (en) | 2003-10-29 |
NZ334283A (en) | 2000-03-27 |
EP0923566A1 (en) | 1999-06-23 |
EP0923566A4 (en) | 2001-10-10 |
SI0923566T1 (en) | 2004-04-30 |
DE69725862D1 (de) | 2003-12-04 |
JP5008783B2 (ja) | 2012-08-22 |
AU730244B2 (en) | 2001-03-01 |
DE69725862T2 (de) | 2004-08-19 |
ES2210564T3 (es) | 2004-07-01 |
AU4079497A (en) | 1998-03-06 |
PT923566E (pt) | 2004-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5008783B2 (ja) | 高分子量のポリマーを基剤とするプロドラッグ | |
US5965566A (en) | High molecular weight polymer-based prodrugs | |
JP4339399B2 (ja) | 高分子量のポリマーを基剤とするプロドラッグ | |
JP4745664B2 (ja) | カンプトテシン類の高分子誘導体 | |
JP4860813B2 (ja) | 末端分枝ポリマーリンカーおよびそれを含有するポリマーコンジュゲート | |
CA2387611C (en) | Manufacture of polyglutamate-therapeutic agent conjugates | |
RU2149646C1 (ru) | Полимерный конъюгат, фармацевтическая композиция | |
US20020183259A1 (en) | Terminally-branched polymeric linkers and polymeric conjugates containing the same | |
WO1995033490A1 (en) | Method of solubilizing substantially water insoluble materials | |
MX2009002853A (es) | Tratamiento de linfomas no hodgkin con conjugados polimericos de multibrazo de 7-etil-10-hidroxicamptotecina. | |
JP2021509138A (ja) | 両親媒性ブロック共重合体及びその調製方法とナノミセル薬物キャリヤーシステム | |
KR20150107650A (ko) | 신규한 양이온성 폴리포스파젠 화합물, 폴리포스파젠-약물 컨쥬게이트 화합물 및 그 제조 방법 | |
US20020161052A1 (en) | Terminally-branched polymeric linkers and polymeric conjugates containing the same | |
RU2382787C2 (ru) | Водорастворимые моно-пэгилированные производные тетрапиррола для фотодинамической терапии и способ их получения | |
MXPA99001731A (en) | High molecular weight polymer-based prodrugs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080226 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080513 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080623 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080722 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080901 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080826 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090728 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20091127 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20100210 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20100408 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20100415 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110104 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110113 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110210 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110222 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20111214 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20111227 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120321 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120530 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150608 Year of fee payment: 3 |
|
LAPS | Cancellation because of no payment of annual fees |